Etodolac Nanogel as an Adjunct to Physiotherapy for Knee Osteoarthritis
Key facts
- Phase
- Phase 2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 60 years old?
Source: NCT07308470, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Pharos University in Alexandria
- Trial code
- NCT07308470
- Record updated
- 29 December 2025
- Original description
Brief Summary:Read full original descriptionShow less
Effect of Etodolac-Loaded Solid Lipid Nanoparticle Gel as an Adjunct to Physiotherapy in Knee Osteoarthritis: A Randomized Clinical Tria
Brief Summary:
Knee osteoarthritis (OA) is a common, disabling condition affecting the weight-bearing knee joint, leading to pain, reduced function, and muscle weakness, particularly of the quadriceps. Strengthening exercises are recommended to improve joint stability, physical function, and slow disease progression. Etodolac, a selective NSAID approved for osteoarthritis, has proven analgesic and anti-inflammatory effects. This study investigates the adjunctive effect of a topical Etodolac-loaded solid lipid nanoparticle gel combined with traditional physiotherapy in patients with knee OA. Thirty patients with mild to moderate unilateral tibiofemoral OA will be randomized into two groups: traditional physiotherapy alone or physiotherapy plus Etodolac gel. Outcomes including pain, knee function, functional performance, quadriceps strength, and proprioception will be assessed at baseline and after four weeks. The study aims to determine whether adding topical Etodolac enhances the benefits of standard physiotherapy in managing knee OA.
Inclusion: Age between 45 and 60 years; Mild to moderate unilateral knee osteoarthritis (Kellgren-Lawrence grades II-III); Ability to walk independently without assistive devices; Body Mass Index (BMI) < 30 kg/m²; No participation in resistance training in the 3 months prior to enrollment; Referred by an orthopedic surgeon and diagnosed based on clinical and radiological examination.
Exclusion: Severe or bilateral knee osteoarthritis (Kellgren-Lawrence grade IV); Congenital or acquired inflammatory, rheumatic, or neurological disorders affecting the knee; Repeated treatment with steroids or secondary knee OA; History of joint replacement surgery in the knee or hip; Cardiovascular or neuromuscular disorders; Diabetes mellitus; Psychiatric disorders.